Exact Sciences Posts Flat Q1 Revenues; Loss More than Doubles as Clinical Trial Costs Spike | GenomeWeb

NEW YORK (GenomeWeb News) – Exact Sciences today reported revenues for the first quarter were flat year over year, while its net loss more than doubled.

For the period ended March 31, the Madison, Wis.-based molecular diagnostics firm brought in revenues of $1.0 million, the same as a year ago, matching Wall Street estimates. All revenues for the quarter were derived from license fees. It had no product royalty fees in the quarter compared to $4,000 a year ago.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: carbapenem resistance in Enterobacteriaceae, selection against educational attainment-linked variants, and more.

Technology Review points out that a new US presidential science advisor hasn't been selected.

Researchers find that blood tests might be able to help determine severity of a concussion, Wired reports.

President-elect Donald Trump considers other candidates for director of the National Institutes of Health, Nature News reports.